Physician profile
Stefanie Kananda
NPI 1396237350
$7,826.82
in general payments reported to CMS, 2019-2025
21 companies · $6,499 in 2025
The $6,499 reported for 2025 was more than what 90% of Pulmonary Disease providers received nationally (typical 2025 total: $500).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2020: $12.60 · 2023: $249 · 2024: $1,066 · 2025: $6,499.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Education: $4,000 · Food and Beverage: $2,331 · Travel and Lodging: $1,483.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Education | $4,000.00 |
| Food and Beverage | $2,331.12 |
| Travel and Lodging | $1,483.10 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Intuitive Surgical, INC. | $5,021.15 | 2025 | |
| Noah Medical Corporation | $1,607.30 | 2024-2025 | Galaxy |
| Astrazeneca Pharmaceuticals LP | $296.84 | 2023-2025 | Fasenra, Tezspire, Airsupra |
| Glaxosmithkline, LLC. | $173.53 | 2024-2025 | Nucala, Trelegy Ellipta |
| Ethicon INC. | $128.66 | 2023 | Monarch Platform |
| Genzyme Corporation | $107.94 | 2025 | |
| Regeneron Healthcare Solutions, INC. | $74.09 | 2023-2024 | Dupixent |
| Verona Pharma, INC. | $61.06 | 2025 | Ohtuvayre |
| Boehringer Ingelheim Pharmaceuticals, INC. | $60.87 | 2024-2025 | Ofev |
| Philips North America LLC | $55.17 | 2023-2024 | (Ak6) Vest Therapy |
| Grifols USA, LLC | $36.97 | 2025 | Prolastin-C Liquid |
| Takeda Pharmaceuticals U.S.A., INC. | $30.59 | 2023-2025 | Glassia |
| Baxter Healthcare | $29.14 | 2025 | Hillrom - Vest System Model 105 Home Care |
| Abbvie INC. | $23.24 | 2025 | |
| Viatris Specialty LLC | $19.44 | 2025 | Yupelri |
Show all 21 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Jazz Pharmaceuticals INC. | $19.13 | 2024 | |
| Amgen INC. | $18.59 | 2025 | Tezspire |
| Insmed, INC. | $17.51 | 2024 | Arikayce |
| Harmony Biosciences LLC | $16.72 | 2025 | |
| Actelion Pharmaceuticals US, INC. | $16.28 | 2025 | Opsumit |
| Janssen Pharmaceuticals, INC | $12.60 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Stefanie Kananda listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.